pharmaphorum Podcast

At this year’s Veeva R&D and Quality Summit, it was revealed that Novo Nordisk and Veeva have entered into a new partnership for clinical development.

In this episode of the pharmaphorum podcast, web editor Nicole Raleigh spoke with Stephanie Bova, chief digital officer at Novo Nordisk, and Rik van Mol, SVP R&D and Quality at Veeva, about the partnership, Novo aiming to accelerate clinical trials and launches by uniting bus...

The JCA process was passed into law by the European Union in 2022. The Joint Clinical Assessment is a process that will systematically assess all available clinical evidence for new drugs. Rolled out in stages, starting with oncology drugs and advanced therapy medicinal products this year, it will be fully implemented by 2030.

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Tommy Bramley, SVP of market access a...

Originally employed in atomic physics, mass spectrometry is now an indispensable tool in modern science, and importantly medical science.

In a new pharmaphorum podcast, web editor Nicole Raleigh spoke with Melissa Sherman, CEO of MOBILion Systems, a company pioneering next-generation separation science, by innovating best-in-class instruments that deeply, accurately, and efficiently characterise complex molecules.

Sherman discusses...

Onsite at ASCO 2025 in Chicago, web editor Nicole Raleigh sat down with Dr Stacy Lindborg, CEO of IMUNON, to discuss the company’s oral presentation at the Congress from the Phase 2 OVATION 2 study of IMNN-001, an IL-12 immunotherapy, in women with newly diagnosed advanced ovarian cancer – since published in the peer-reviewed journal Gynecologic Oncology today.

Dr Lindborg shares her journey to her present role, the true potential ...

Osteosarcoma is an extremely challenging and often aggressive cancer that has particular treatment challenges due to location, changing genotypes, and high recurrence rates. It mostly affects children and young adults under 20 years of age.

In a new pharmaphorum podcast, web editor Nicole Raleigh spoke with Paul Romness, president and CEO of OS Therapies, a company focused on the identification, development, and commercialisation o...

In healthcare, some of the most meaningful innovations happen when the right people are brought together in the right place. True progress depends on systems and infrastructure designed to connect ideas, people, and expertise across sectors.

Citylabs 4.0, now open in the heart of Manchester’s Knowledge Quarter on the Oxford Road Corridor, was built with exactly that goal in mind. Bringing the NHS, academia, and life sciences organi...

Boehringer Ingelheim’s data presented at ASCO 2025 reflected the company’s broad pipeline and growing body of evidence supporting innovative therapies for various cancers.

In a pharmaphorum podcast recorded onsite at the Congress, web editor Nicole Raleigh spoke with Itziar Canamasas, global head of oncology at Boehringer Ingelheim, for a discussion of the unmet needs in oncology and some of the specifics of the company’s data pres...

Trends can be predicted, and trends can unfold. Here, Liz Beatty – co-founder and chief strategy of Inato – speaks to the beginnings of a new era in drug development brought on by key technological advances in AI.

Historically, large urban academic centres have conducted the majority of clinical trials, leading to such issues as inaccessibility, lack of representation, and intense competition for participants. With growing industry...

As has been widely reported on, immunisation rates, including for flu and RSV, have been falling – at a troubling rate – and diseases like whooping cough and measles have seen a worrying resurgence due to anti-vaxxers. And not just in the US.

In a new pharmaphorum podcast, Rebecca Catterick, General Manager for Vaccines, UK & Ireland, at Sanofi, discusses this decline in vaccination rates, as well as what can be done to turn th...

Early access programmes (EAPs) for novel medicines are an often-misunderstood strategy outside of western markets.

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Cem Zorlular, CEO of Er-Kim Pharmaceuticals, a company that has been serving as a regional affiliate for pharma and biotech since 1981 in the CEE and Mediterranean.

Market access strategies in many international markets do not function the same way as...

With the FDA and EMA releasing their annual reports detailing novel drug approvals in 2024, a new pharmaphorum podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face in the year ahead.

Host Nicole Raleigh is joined by Cencora’s Sandra Anderson, SVP of International Commercialisation, and Chris Williams, SVP & International Managing Director a...

ISPOR 2025, the leading global conference for Health Economics and Outcomes Research (HEOR), takes place 13th-16th May and marks the 30th anniversary of the organisation.

Ahead of the event, web editor Nicole Raleigh spoke with Rob Abbott, CEO and executive director of ISPOR – the leading professional society for HEOR globally – about the ins and outs and trends of HEOR.

ISPOR’s mission is to advance HEOR excellence to improve dec...

President Donald Trump’s April 15th executive order, “Lowering Drug Prices by Once Again Putting Americans First”, contained a smorgasbord of policy proposals targeting a variety of industry stakeholders.

But how much legal force do these different elements have, and what are the concrete takeaways for pharma? To answer these questions and more, host Jonah Comstock once again welcomes Hogan Lovells attorney Alice Valder Curran to t...

It can take up to 15 years for a new drug to reach the market, and with only 20% of pharmaceutical professionals adopting AI, one thing is clear: innovation in drug development is lagging behind.

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Andrew Stelzer, head of business development at Unlearn.AI, about how the real hurdle in clinical research lies in effectively integrating AI.

Stelzer discusses the need ...

Therapy initiation, adherence, and health outcomes are being driven by artificial intelligence (AI)-powered personalisation. Today’s consumers are more active participants in their healthcare. Marketing in the era of consumer-driven healthcare requires new strategies to reach patients with the information they require, and how and when they need it.

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Bill Grambley,...

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Tomasz Kostriezewski, CSO at CN Bio, about single organ-on-a-chip technology and multi-organ microphysiological systems (MPS), as well as accelerating drug discovery pipelines with these new alternative methodologies (NAMs).

Clinical trial success rates are very low, with up to 95% not succeeding, and a wide range of disease states remains untreated. What NAMs per...

Across the life sciences, Regulatory Affairs (RA) teams and their colleagues in Quality and Safety are stretched beyond their limits as already impossible demands on their time are compounded by rising health authority expectations.

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Sonia A. Veluchamy, CEO and co-founder of Celegence, a company dedicated to improving patient outcomes through intelligent regulatory...

In a new pharmaphorum podcast, recorded during Anthropy 2025: Rebooting Britain, web editor Nicole Raleigh spoke with David Gillen, chief medical officer at Norgine, about the role of prevention in the future of healthcare.

Recorded onsite at The Eden Project in Cornwall, the conversation centred around the Adelphi Group-sponsored panel, ‘The Prevention Revolution in Your Healthcare’, exploring the key takeaways and exciting possib...